LabCorp/$LH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LabCorp
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Ticker
$LH
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
65,450
ISIN
US5049221055
Website
LabCorp Metrics
BasicAdvanced
$22B
30.16
$8.67
0.80
$2.88
1.10%
Price and volume
Market cap
$22B
Beta
0.8
52-week high
$264.03
52-week low
$198.96
Average daily volume
678K
Dividend rate
$2.88
Financial strength
Current ratio
1.836
Quick ratio
1.281
Long term debt to equity
76.867
Total debt to equity
79.126
Dividend payout ratio (TTM)
33.20%
Interest coverage (TTM)
5.25%
Profitability
EBITDA (TTM)
1,717.3
Gross margin (TTM)
27.89%
Net profit margin (TTM)
5.55%
Operating margin (TTM)
8.66%
Effective tax rate (TTM)
21.92%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
4.18%
Return on equity (TTM)
8.98%
Valuation
Price to earnings (TTM)
30.157
Price to revenue (TTM)
1.662
Price to book
2.64
Price to tangible book (TTM)
-13.68
Price to free cash flow (TTM)
19.009
Free cash flow yield (TTM)
5.26%
Free cash flow per share (TTM)
1,375.11%
Dividend yield (TTM)
1.10%
Forward dividend yield
1.10%
Growth
Revenue change (TTM)
7.13%
Earnings per share change (TTM)
73.29%
3-year revenue growth (CAGR)
-4.45%
10-year revenue growth (CAGR)
7.57%
3-year earnings per share growth (CAGR)
-26.46%
10-year earnings per share growth (CAGR)
6.68%
What the Analysts think about LabCorp
Analyst ratings (Buy, Hold, Sell) for LabCorp stock.
Bulls say / Bears say
Labcorp's Diagnostics Laboratories revenue increased by 7.9% in Q2 2024, indicating strong demand for diagnostic tests. (reuters.com)
The company raised its 2024 revenue growth outlook to 6.4%-7.5%, reflecting confidence in sustained demand and operational performance. (reuters.com)
Analysts have increased their price targets for Labcorp, with Leerink Partners raising it to $268, citing solid Q3 performance and undervaluation. (investing.com)
Labcorp lowered its 2024 adjusted EPS outlook due to expenses related to the $239 million acquisition of Invitae, which may impact short-term profitability. (reuters.com)
The company's biopharma laboratory services segment experienced modest sales growth of 1.1% in Q2 2024, indicating potential challenges in this area. (reuters.com)
Labcorp's operating margin in Q3 2024 was 13.4%, about 30 basis points below expectations, partly due to adverse weather impacts. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
LabCorp Financial Performance
Revenues and expenses
LabCorp Earnings Performance
Company profitability
LabCorp News
AllArticlesVideos
ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage
GlobeNewsWire·3 weeks ago
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LabCorp stock?
LabCorp (LH) has a market cap of $22B as of June 20, 2025.
What is the P/E ratio for LabCorp stock?
The price to earnings (P/E) ratio for LabCorp (LH) stock is 30.16 as of June 20, 2025.
Does LabCorp stock pay dividends?
Yes, the LabCorp (LH) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $2.88 and the yield is 1.1%. LabCorp has a payout ratio of 33.2% on a trailing twelve-month basis.
When is the next LabCorp dividend payment date?
The next LabCorp (LH) dividend payment date is unconfirmed.
What is the beta indicator for LabCorp?
LabCorp (LH) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.